The effect of intermittent theta burst stimulation on central poststroke pain: A pilot randomized controlled trial.

Medicine (Baltimore)Oct 2, 2026
Clinical ResearchNeurologyPhysical Medicine & Rehabilitation

Sangpil Son, Sol Lee, JaeIn You et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial investigated the effects of intermittent theta burst stimulation (iTBS) on central poststroke pain (CPSP) in 20 patients. The study found that iTBS significantly reduced pain scores on multiple assessment scales compared to sham stimulation, indicating its potential as an effective treatment for CPSP.

Key findings

  • Significant reductions in PD-Q, LANSS, DN4, and numeric rating scale scores were observed in the real iTBS group.
  • No adverse effects were reported during the iTBS sessions.
  • The study involved 20 patients with CPSP who received either real or sham iTBS.

Why it matters

The findings suggest that iTBS may offer a safe and effective treatment option for managing central poststroke pain, a condition that can significantly impact patient quality of life.

Source

PubMed · PMID 42826272

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.